Review : Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma

Review : Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma

Angiogenesis in general and the VEGF signaling axis in particular is a validated target in renal cell carcinoma. Clear cell carcinoma of the kidney is now recognized as a malignancy that is sensitive to inhibitors of the vascular endothelial growth factor pathway. Treatment options for patients with...

Full description

Bibliographic Details
Main Author:	Ronald M Bukowski
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2012-02-01
Series:	Frontiers in Oncology
Subjects:	Tyrosine Cancer kinase inhibitors Renal
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00013/full

Similar Items

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
by: Florent Puisset, et al.
Published: (2023-01-01)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
by: Qinlian Jiao, et al.
Published: (2018-02-01)

Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
by: Takuto Shimizu, et al.
Published: (2024-02-01)

Novel Tyrosine Kinase Targets in Urothelial Carcinoma
by: Javier Torres-Jiménez, et al.
Published: (2021-01-01)

Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
by: Jakob Michaelis, et al.
Published: (2022-08-01)

Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations
by: Kun Wang, et al.
Published: (2023-07-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma
by: Inoue Takaaki, et al.
Published: (2012-08-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
by: Emmy D. G. Fleuren, et al.
Published: (2023-03-01)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
by: Charles Pottier, et al.
Published: (2020-03-01)

QTC Changes Associated with Tyrosine Kinase Inhibitors in Cancer Patients
by: Rahimullah Khattak, et al.
Published: (2022-09-01)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-08-01)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
by: Paula Aldaz, et al.
Published: (2021-11-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
by: Huang JT, et al.
Published: (2022-11-01)

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
by: D. Samuel Metibemu, et al.
Published: (2019-12-01)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
by: Ahmad Assi, et al.
Published: (2023-12-01)

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
by: Yassir Sbitti, et al.
Published: (2018-03-01)

HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma
by: Xianglai Xu, et al.
Published: (2023-05-01)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
by: Maciej Niewada, et al.
Published: (2023-03-01)

Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result
by: Yuntian Chen, et al.
Published: (2023-02-01)

Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
by: Kinga Krawczyk, et al.
Published: (2023-09-01)

Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma
by: Yoshihiko Yano, et al.
Published: (2022-06-01)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
by: Christopher Kwok, et al.
Published: (2023-07-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
by: Hor-Yue Tan, et al.
Published: (2018-02-01)

Tyrosine Kinase Receptors in Oncology
by: Jorge Esteban-Villarrubia, et al.
Published: (2020-11-01)

Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
by: Yu Liu, et al.
Published: (2019-06-01)

Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors
by: A. Yu. Goryainova, et al.
Published: (2021-12-01)

Clinicopathological Characteristics and Real-life Data of Patients Receiving Tyrosine Kinase Inhibitor in Metastatic EGFR Mutant Non-small Cell Lung Carcinoma
by: Barış EKİNCİ, et al.
Published: (2023-12-01)

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
by: Dariusz Rozkiewicz, et al.
Published: (2023-03-01)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
by: Nikolaos Dervisis, et al.
Published: (2016-01-01)

Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
by: Jiangnan Liu, et al.
Published: (2024-03-01)

Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion
by: Vineet Agrawal, et al.
Published: (2015-02-01)

Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma
by: Jiajun Wang, et al.
Published: (2019-01-01)

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
by: Bibian M. E. Tullemans, et al.
Published: (2018-10-01)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
by: Shuang Qin, et al.
Published: (2019-03-01)

Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7
by: Qing Liu, et al.
Published: (2023-02-01)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
by: Yuanquan Yang, et al.
Published: (2022-08-01)

Resolution of a Debilitating Paraneoplastic Parkinson-like Neurological Syndrome Following Tyrosine Inhibitor Therapy and Consolidative Nephrectomy in a Patient with Advanced Clear Cell Renal Cell Carcinoma
by: Naveed Ali, et al.
Published: (2017-09-01)

Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials
by: Muhammad Ashar Ali, et al.
Published: (2023-01-01)